Drug Database
Back to search

Poland· PL-100427356

Feiba NF

A faktor viii-inhibitor bypass aktivität - feiba product containing zespół czynników krzepnięcia przeciw inhibitorowi czynnika viii, registered in Poland by Takeda Pharma Sp. z o.o.. The same ATC class is registered in 10 of our 19 countries.

ATC B02BD03

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedFeiba NFATCB02BD03REGISTER NO.PL-100427356PACKS LISTED2CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about zespół czynników krzepnięcia przeciw inhibitorowi czynnika viiiAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Faktor viii-inhibitor bypass aktivität - feiba is registered in 10 of 19 countries.

Countries holding a registration under ATC B02BD03 (faktor viii-inhibitor bypass aktivität - feiba), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 6 of them publish a price we can compare per daily dose
Search faktor viii-inhibitor bypass aktivität - feiba products by name

Faktor viii-inhibitor bypass aktivität - feiba · ATC B02BD03

10 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Zespół czynników krzepnięcia przeciw inhibitorowi czynnika VIII
Manufacturer
Takeda Pharma Sp. z o.o.
Country
Poland (PL)
ATC code
B02BD03
ATC class
Faktor VIII-Inhibitor Bypass Aktivität - FEIBA
Defined daily dose
7 TSD, E
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05909991418243
  • gtin
    00642621066456

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

5 interactions on record for faktor viii-inhibitor bypass aktivität - feiba.

Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check faktor viii-inhibitor bypass aktivität - feiba against other medicinesHow interaction checks work

Faktor viii-inhibitor bypass aktivität - feiba · interactions on record

5 records

  • 4 severe
  • 1 moderate

Most severe, free to view

  • Aminocaproic acidB02AA01severe
  • Tranexamic acidB02AA02severe
  • AprotininB02AB01severe
  • EmicizumabB02BX06severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same class

Other records under B02BD03

Faktor viii-inhibitor bypass aktivität - feiba, as other registers publish it.

All faktor viii-inhibitor bypass aktivität - feiba products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f8dafcc7-b46c-415b-8d10-75f3fbb1defd
GET /v1/drugs/f8dafcc7-b46c-415b-8d10-75f3fbb1defd?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań",
  "source": "urpl",
  "strength": "500 j. (500 j. FEIBA), 50 j./ml",
  "packaging": "05909991418243 ¦ Rp ¦ 134575\n1 fiol. 500 j. proszku ¦ 1 fiol. 10 ml rozp. ¦ 1 strzykawka  ¦ 5 igieł  (1 igła do wstrzykiwań, 1 igła z filtrem, 1 igła dwustronna, 1 igła z odpowietrznikiem, 1 igła motylkowa (zestaw infuzyjny z igłą motylkową))\n00642621066456 ¦ Rp ¦ 134576\n1 fiol. 500 j. proszku ¦ 1 fiol. 10 ml rozp. ¦ 1 przyrząd  BAXJECT II Hi-Flow ¦ 2 igły  (1 igła do wstrzykiwań, 1 igła motylkowa (zestaw infuzyjny z igłą motylkową)) ¦ 1 strzykawka",
  "substance": "Białko osocza ludzkiego 20-60 mg/ml",
  "common_name": "Zespół czynników krzepnięcia przeciw inhibitorowi czynnika VIII",
  "pl_product_id": "100427356",
  "pozwolenie_nr": "25629",
  "auth_procedure": "NAR",
  "authorisation_validity": "Bezterminowe"
}
API referenceMCP serverPlans

See everything about faktor viii-inhibitor bypass aktivität - feiba.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console